ORIGINAL ARTICLE
Potential significance of podoplanin immunohistochemical expression in papillary thyroid carcinoma
1
Department of Pathology, Ain Shams University, Cairo, Egypt
Submission date: 2023-05-01
Final revision date: 2023-09-03
Acceptance date: 2023-09-20
Publication date: 2023-10-25
Corresponding author
Rana M. Khalil
Rana M. Khalil Department of Pathology, Ain Shams University, Cairo, Egypt
Rana M. Khalil Department of Pathology, Ain Shams University, Cairo, Egypt
Pol J Pathol 2023;74(3):171-181
KEYWORDS
cancer-associated fibroblastslymphatic vessel densitypapillary thyroid carcinomapredictive valuepodoplanindiagnostic role
TOPICS
ABSTRACT
Podoplanin (PDPN) is a lymphatic endothelial marker expressed by a range of human malignancies in which it has been shown to contribute to tumor progression and metastasis. However, there is a lack of the studies, examining the function of PDPN in thyroid cancer. The current study was performed to explore the possible diagnostic value of PDPN expression in papillary thyroid cancer (PTC) and to evaluate the marker’s potential for prediction of regional lymph node metastasis. Lymphatic vascular density (LVD) and the stromal/cancer-associated fibroblasts (CAFs), labeled by PDPN, were examined in PTC compared to the other thyroid lesions. The current study included 50 cases of PTC and 50 cases of non-PTC thyroid lesions. Immunohistochemical staining was performed using monoclonal PDPN antibodies. Podoplanin expression was scored as positive and negative. Podoplanin expression was found in 36% of PTC cases, but it was not found in benign, low risk (borderline), or malignant lesions other than PTC. Furthermore, lymph node metastasis was significantly correlated with PDPN expression, LVD and CAFs (p-values < 0.00001, < 0.001 and 0.0002 respectively). These findings support the diagnostic utility of PDPN expression in PTC and its predictive value for LN metastasis.
REFERENCES (54)
1.
Kitahara CM, Sosa JA. Understanding the ever-changing incidence of thyroid cancer. Nat Rev Endocrinol 2020; 16: 617-618.
2.
Siegel RL, Miller KD, Jemal A. Cancer statistics 2020. CA Cancer J Clin 2020; 70: 7-30.
3.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90. Erratum in: CA Cancer J Clin 2011; 61: 134.
4.
Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 2012; 22: 884-889.
5.
Bychkov A, Jung CK, Liu Z, Kakudo K. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in asian practice: perspectives for surgical pathology and cytopathology. Endocr Pathol 2018; 29: 276-288.
6.
Abd El Atti RM, Shash LS. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. J Egypt Natl Canc Inst 2012; 24: 175-184.
7.
Baloch Z, Mete O, Asa SL. Immunohistochemical biomarkers in thyroid pathology. Endocr Pathol 2018; 29: 91-112.
8.
Mehrandish L, Madani S, Khazaei S, et al. Diagnostic value of beta-catenin immunohistochemical staining in papillary thyroid carcinoma. Clin Cancer Investig J 2021; 10: 11-14.
9.
Sethi K, Sarkar S, Das S, et al. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol 2011; 9: 187-199.
10.
Jung JW, Choi JY, Lee KE, Park KW. Immunohistochemical and molecular markers associated with differentiated thyroid carcinoma. Clin Exp Thyroidol 2015; 8: 50-60.
11.
Kong LL, Yang NZ, Shi LH, et al. The optimum marker for the detection of lymphatic vessels. Mol Clin Oncol 2017; 7: 515-520.
12.
Renart J, Carrasco-Ramírez P, Fernández-Mu¼oz B, et al. New insights into the role of podoplanin in epithelial-mesenchymal transition. Int Rev Cell Mol Biol 2015; 317: 185-239.
13.
Quintanilla M, Montero-Montero L, Renart, J, Martín-Villar E. Podoplanin in inflammation and cancer. Int J Mol Sci 2019; 20: 707.
14.
Parvez K, Arora V, Wadhwa N. Peri-tumoral lymphovascular density by antipodoplanin antibody D2-40, as a predictor of nodal metastasis in oral squamous cell carcinoma. The Physician 2020; 6: 1-11.
15.
Huber GF, Fritzsche FR, Züllig L, et al. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int J Cancer 2011; 129: 1404-1409.
16.
Hu G, Wang S, Xu F, et al. Tumor-infiltrating podoplanin+ fibroblasts predict worse outcome in solid tumors. Cell Physiol Biochem 2018; 51: 1041-1050.
17.
Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 2022; 33: 27-63.
18.
Tuttle RM, Morris LF, Haugen BR, et al. Thyroid- differentiated and anaplastic carcinoma. In: American Joint Committee on cancer, AJCC cancer staging manual, eighth edition; Amin MB, Edge SB, Greene FL, et al. (ed.). Springer. USA 2017; 873-890.
19.
Kim HY, Rha KS, Shim GA, et al. Podoplanin is involved in the prognosis of head and neck squamous cell carcinoma through interaction with VEGF-C. Oncol Rep 2015; 34: 833-842.
20.
Wahal SP, Goel MM, Mehrotra R. Lymphatic vessel assessment by podoplanin (D2-40) immunohistochemistry in breast cancer. J Cancer Res Ther 2015; 11: 798-804.
21.
Schoppmann SF, Berghoff A, Dinhof C, et al. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat 2012; 134: 237-244.
22.
Krishnan H, Retzbach EP, Ramirez MI, et al. PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility. Exp Cell Res 2015; 335: 115-122.
23.
Gong L, Chen P, Liu X, et al. Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma. Gland Surg 2012; 1: 25-32.
24.
Chopra S, Deodhar K, Pai V, et al. Cancer stem cells, CD44, and outcomes following chemoradiation in locally advanced cervical cancer: results from a prospective study. Int J Radiat Oncol Biol Phys 2019; 103: 161-168.
25.
Wang X, Wang X, Carvalho V, et al. Prognostic value of podoplanin in various tumors. Technol Cancer Res Treat 2021; 20: 1-10.
26.
Ikoma Y, Kijima H, Masuda R, et al. Podoplanin expression is correlated with the prognosis of lung squamous cell carcinoma. Biomed Res 2015; 36: 393-402.
27.
Garcia AS, Assao A, Carvalho AL, et al. The stem cell markers expression CD44v6 and podoplanin in lip cancer: clinical significance. Virchows Arch 2019; 474: 745-754.
28.
Wang SL, Li SH, Chen WT, Chai CY. Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma. APMIS 2007; 115: 906-910.
29.
Rudzińska M, Gaweł D, Sikorska J, et al. The role of podoplanin in the biology of differentiated thyroid cancers. PLoS One 2014; 9: e96541. doi: 10.1371/journal.pone.009654.
30.
Mello FW, Kammer PV, Silva CAB, et al. Prognostic and clinicopathological significance of podoplanin immunoexpression in oral and oropharyngeal squamous cell carcinoma: A systematic review. J Oral Pathol Med 2021; 50: 1-9.
31.
Parmar P, Marwah N, Parshad S, et al. Clinicopathological significance of tumor lymphatic vessel density in head and neck squamous cell carcinoma. Indian J Otolaryngol Head Neck Surg 2018; 70: 102-110.
32.
Chen J, Zhang F, Hua M, et al. Prognostic value of lymphatic vessel density in oral squamous cell carcinoma. Life Sci 2021; 265: 118746.
33.
Giorgadze TA, Baloch ZW, Pasha T, et al. Lymphatic and blood vessel density in the follicular patterned lesions of thyroid. Mod Pathol 2005; 18: 1424-1431.
34.
Cheong H, Kang H, Kim HK, et al. Microvessel and lymphatic vessel density and VEGFR-3 Expression of papillary thyroid carcinoma with comparative analysis of clinicopathological characteristics. Korean Journal of Pathology 2010; 44: 243-251.
35.
Kuletic V, Radosavljevic GD, Pantic J, et al. Angiogenic and lymphangiogenic profiles in histological variants of papillary thyroid carcinoma. Pol Arch Intern Med 2017; 127: 429-437.
36.
Dai K, Tanaka M, Kamiyoshi A, et al. Deficiency of the adrenomedullin-RAMP3 system suppresses metastasis through the modification of cancer-associated fibroblasts. Oncogene 2020; 39: 1914-1930.
37.
Minna E, Brich S, Todoerti K, et al. Cancer associated fibroblasts and senescent thyroid cells in the invasive front of thyroid carcinoma. Cancers (Basel) 2020; 12: 112.
38.
Watanabe N, Kidokoro M, Tanaka M, et al. Podoplanin is indispensable for cell motility and platelet-induced epithelial-to-mesenchymal transition-related gene expression in esophagus squamous carcinoma TE11A cells. Cancer Cell Int 2020; 20: 263.
39.
Suzuki J, Aokage K, Neri S, et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer 2021; 153: 1-10.
40.
Poggi A, Musso A, Dapino I, Zocchi MR. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol Lett 2014; 159: 55-72.
41.
Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol 2020; 17: 487-505.
42.
Cho JG, Byeon HK, Oh KH, et al. Clinicopathological significance of cancer-associated fibroblasts in papillary thyroid carcinoma: a predictive marker of cervical lymph node metastasis. Eur Arch Otorhinolaryngol 2018; 275: 2355-2361.
43.
Chung MK, Kim JH, Ko YH, Son, YI. Correlation of lymphatic vessel density and vascular endothelial growth factor with nodal metastasis in papillary thyroid microcarcinoma. Head Neck 2012; 34: 846-851.
44.
Kitano H, Kageyama S, Hewitt SM, et al. Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. Arch Pathol Lab Med 2010; 134: 1520-1527.
45.
Lei Y, Feng S, Yu Q, et al. Conventional papillary thyroid carcinoma with intraglandular lymphatic dissemination shows more aggressive features. Jpn J Clin Oncol 2022; 52: 1311-1320.
46.
Liang L, Huang WT, He RQ, et al. A meta-analysis of the lymphatic microvessel density and survival in gastric cancer with 1809 cases. Oncotarget 2017; 9: 5406-5415.
47.
Almeida BG, Bacchi CE, Carvalho JP, et al. The role of intratumoral lymphovascular density in distinguishing primary from secondary mucinous ovarian tumors. Clinics (Sao Paulo) 2014; 69: 660-665.
48.
Pereira F, Pereira S, Mesquita M, et al. Lymph node metastases in papillary and medullary thyroid carcinoma are independent of intratumoral lymphatic vessel density. Eur Thyroid J 2017; 6: 57-64.
49.
Pula B, Witkiewicz W, Dziegiel P, Podhorska-Okolow M. Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review. Int J Oncol 2013; 42: 1849-1857.
50.
Sun WY, Jung WH, Koo JS. Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma. Tumor Biol 2016; 37: 8197-8207.
51.
Liu Z, Yu P, Xiong Y, et al. Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma. Int J Clin Exp Med 2015; 8: 4369-4374.
52.
Pula B, Jethon A, Piotrowska A, et al. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 2011; 59: 1249-1260.
53.
Chen L, Qin Y, Zhang T, et al. Clinical significance of cancer-associated fibroblasts and their correlation with microvessel and lymphatic vessel density in lung adenocarcinoma. J Clin Lab Anal 2019; 33: e22832.
54.
Knops AM, South A, Rodeck U, et al. Cancer-associated fibroblast density, prognostic characteristics, and recurrence in head and neck squamous cell carcinoma: A Meta-Analysis. Front Oncol 2020; 10: 565-306.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
